Matches in Nanopublications for { <http://www.nextprot.org/nanopubs#NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1 type RangedSequencePosition NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk.assertion.
- NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1 type SO_0001148 NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk.assertion.
- NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1 comment "APO-RANTES-stimulated phosphorylation reduced by 18%; APO-RANTES-stimulated phosphorylation reduced by 30-50% on APO-RANTES stimulation; when associated with A-336 or A-342 or A-349; APO-RANTES-stimulated phosphorylation reduced by 80%; when associated with A-336 and A-342 or A-349; No APO-RANTES-stimulated phosphorylation; when associated with A-336; A-342 and A349; abolishes interaction with ARRB2; when associated with S-336; S-342 and S-349." NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk.assertion.
- NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1 SIO_000053 NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._3 NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk.assertion.
- NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._1 SIO_000053 NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk._2 NX_P51681-1_MUTAGEN_337_337.RAXlSZzKQ2kOTcubZf5fUeBwJjxGuogSGGHsvJ_mdMjHk.assertion.